Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tablet and capsule interchangeability as solid oral dosage forms urged by Perrigo.

This article was originally published in The Tan Sheet

Executive Summary

TABLET, CAPSULE INTERCHANGEABILITY AS SOLID ORAL DOSAGE FORM URGED by private label manufacturer Perrigo. The firm also suggests that FDA consider tablets and capsules as the same (i.e., solid oral) dosage forms as caplets, "Penta"-shaped tablets (i.e., J&J/Merck's Pepcid AC) or other shaped tablets, the company maintains in June 26 comments to the agency. The company was responding to an FDA request for comments on whether there should be any change in agency policy to limit permitting bioequivalent tablets and capsules to be listed as "therapeutically equivalent" in the "Orange Book" or should FDA regard tablets and capsules as the same (solid, oral).
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087307

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel